GHSI - Guardion Health Sciences Inc Stock Price, Fair Value and News

7.99USD-0.06 (-0.75%)Delayed

Market Summary

USD7.99-0.06

Delayed

-0.75%

GHSI Stock Price

View Fullscreen

GHSI RSI Chart

GHSI Valuation

Market Cap

10.3M

Price/Earnings (Trailing)

64.93

Price/Sales (Trailing)

0.84

Price/Free Cashflow

-2.35

GHSI Price/Sales (Trailing)

GHSI Profitability

Return on Equity

1.94%

Return on Assets

1.33%

Free Cashflow Yield

-42.63%

GHSI Fundamentals

GHSI Revenue

Revenue (TTM)

12.2M

Rev. Growth (Yr)

7.68%

Rev. Growth (Qtr)

-12.03%

GHSI Earnings

Earnings (TTM)

158.0K

Earnings Growth (Yr)

103.41%

Earnings Growth (Qtr)

13.98%

Breaking Down GHSI Revenue

Last 7 days

1.4%

Last 30 days

-11.1%

Last 90 days

53.5%

Trailing 12 Months

28.3%

How does GHSI drawdown profile look like?

GHSI Financial Health

Current Ratio

9.01

GHSI Investor Care

Shares Dilution (1Y)

3.51%

Diluted EPS (TTM)

-12.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.9M	11.4M	12.0M	12.2M
2022	9.4M	11.4M	11.0M	11.0M
2021	1.9M	1.9M	4.8M	7.2M
2020	906.1K	1.8M	1.9M	1.9M
2019	991.7K	1.0M	898.8K	902.9K
2018	574.5K	735.3K	966.8K	942.2K
2017	167.8K	198.4K	227.4K	437.4K
2016	119.9K	126.9K	134.0K	141.0K
2015	0	0	0	112.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Guardion Health Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 10, 2023	radoff bradley louis	bought	242,353	7.59727	31,900	-
Jan 09, 2023	radoff bradley louis	bought	583,487	6.87904	84,821	-
Jan 06, 2022	scholtes bret	sold (taxes)	-24,163	0.65	-37,175	ceo and president
Aug 31, 2021	scholtes bret	bought	6,760	1.2291	5,500	ceo and president
Aug 30, 2021	gagliano donald a	bought	6,250	1.25	5,000	-
Aug 30, 2021	scholtes bret	bought	5,655	1.2568	4,500	ceo and president
Aug 20, 2021	weingarten robert n	acquired	11,400	1.14	10,000	-
Jan 06, 2021	scholtes bret	acquired	-	-	916,023	chief executive officer
Jan 06, 2021	scholtes bret	acquired	-	-	152,671	ceo and president
Oct 30, 2019	evans david w	acquired	664	0.332	2,000	chief science officer

Which funds bought or sold GHSI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-30,299	79,310	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-5,000	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-133	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-4.28	-90,000	203,000	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-20,462	53,560	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	17.68	-1,060	6,077	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-1,344	3,519	-%
Feb 12, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-12.00	32.00	-%
Feb 12, 2024	Cornerstone Planning Group LLC	unchanged	-	-75.00	198	-%

Are Funds Buying or Selling GHSI?

Are funds buying GHSI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GHSI

No. of Funds

Unveiling Guardion Health Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	3.8%	50,000	SC 13G/A
Feb 05, 2024	hudson bay capital management lp	9.99%	141,535	SC 13G/A
Feb 08, 2023	hudson bay capital management lp	9.74%	6,651,000	SC 13G
Feb 08, 2023	intracoastal capital, llc	7.5%	5e+06	SC 13G/A
Jan 10, 2023	radoff bradley louis	2.0%	25,100	SC 13G/A
Nov 30, 2022	radoff bradley louis	1.0%	620,000	SC 13G
Feb 28, 2022	intracoastal capital, llc	8.1%	5e+06	SC 13G
Feb 12, 2021	grier edward b. iii	1.22%	1,079,089	SC 13G/A
Jan 27, 2020	empery asset management, lp	4.99%	5,848,612	SC 13G/A
Jan 13, 2020	sabby management, llc	4.99%	3,741,630	SC 13G/A

Recent SEC filings of Guardion Health Sciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	DEFM14A	DEFM14A
Apr 03, 2024	3	Insider Trading
Apr 02, 2024	S-3	S-3
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 21, 2024	PREM14A	PREM14A
Mar 15, 2024	PRE 14A	PRE 14A
Feb 06, 2024	SC 13G/A	Major Ownership Report
Feb 05, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Guardion Health Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	356.3B	85.2B	-5.03%	-9.57%	10.14	4.18	6.46%	95.94%
MRK	318.7B	60.1B	1.61%	10.23%	873.24	5.3	1.40%	-97.49%
PFE	146.8B	46.5B	-6.17%	-34.78%	-105.7	3.15	42.59%	-114.62%
AMGN	144.1B	28.2B	-1.51%	10.46%	21.46	5.11	7.09%	2.52%
GILD	83.2B	27.1B	-9.77%	-21.18%	14.68	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.65	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.2	2.4	49.61%	324.78%
BHC	3.2B	8.8B	-9.38%	13.00%	-5.36	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	13.99	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.6M	1.3M	-20.43%	-49.32%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.6M	-	-10.09%	36.11%	-0.9	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	-34.48%	-94.22%	-0.18	0.13	80.00%	43.08%
ACOR	546.5K	117.6M	-96.48%	-95.45%	0	0	-0.79%	-283.60%

Guardion Health Sciences Inc News

Latest updates

Guardion Health Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-12.0%	2,936	3,337	2,790	3,186	2,726	2,664	3,275	2,385	2,627	3,149	1,224	233	200	253	1,191	246	238	161	261	243	234
Gross Profit	-7.6%	1,350	1,460	1,249	1,335	936	1,088	1,400	1,096	1,064	1,388	559	100	-878	139	546	137	158	90.00	164	149	128
Operating Expenses	9.1%	2,436	2,233	2,262	2,799	12,286	2,828	3,111	3,717	15,585	4,404	5,099	2,770	2,477	2,291	1,255	2,473	4,247	2,503	2,976	1,331	1,484
S&GA Expenses	16.8%	372	319	415	599	486	526	389	669	609	778	441	458	275	167	519	489	646	448	409	354	296
R&D Expenses	-99.3%	79.50*	11.00	77.00	63.00	31.00	60.00	96.00	7.00	11.00	16.00	17.00	21.00	51.00	34.00	45.00	31.00	56.00	32.00	78.00	29.00	33.00
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	17.50*	4.00	2.00	2.00	3.00	4.00	234	18.00	199*
Income Taxes	-	-	-	-	-	-20.84	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-	-
Net Income	14.0%	425	373	-1,172	533	-12,453	-822	3,656	-5,300	-14,520	-3,014	-4,540	-2,669	-3,374	-2,143	-707	-2,346	-4,055	-2,385	-3,052	-1,385	-1,476
Net Income Margin	101.2%	0.01*	-1.06*	-1.22*	-0.77*	-1.35*	-1.55*	-1.68*	-2.92*	-3.42*	-2.83*	-6.66*	-4.74*	-4.54*	-4.80*	-	-	-	-	-	-	-
Free Cashflow	-71.9%	-1,317	-766	-408	-1,880	-1,363	-1,285	-2,574	-2,228	-1,564	-1,868	-4,865	-2,420	-2,173	-1,819	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.5%	11,918	12,878	13,474	14,419	21,686	28,228	29,835	31,621	23,461	38,613	41,285	44,702	9,861	12,159	14,034	15,283	12,877	8,955	5,698	3,971	3,681
Current Assets	-7.4%	11,885	12,840	13,431	14,373	21,637	17,811	19,099	20,568	12,069	14,867	16,547	43,996	9,095	11,334	13,171	14,303	11,868	6,132	2,856	544	1,105
Cash Equivalents	-16.9%	6,360	7,657	8,366	8,775	10,655	12,946	4,225	4,832	4,094	3,564	5,502	43,330	8,519	9,795	11,603	12,890	11,116	5,555	2,369	174	671
Inventory	9.2%	2,677	2,451	2,513	3,061	3,119	1,953	1,710	822	368	793	956	289	385	1,284	1,235	759	311	320	319	304	358
Net PPE	-12.8%	33.00	38.00	43.00	46.00	49.00	54.00	75.00	94.00	111	269	246	266	286	306	305	383	375	389	304	265	275
Goodwill	-	-	-	-	-	-	-	-	-	-	11,893	11,988	-	-	-	-	-	-	1,564	1,564	1,564	1,564
Liabilities	-27.1%	3,772	5,176	6,233	5,937	8,518	6,969	7,802	13,293	1,163	1,970	1,991	1,212	1,346	1,471	1,338	1,544	845	906	1,010	2,083	495
Current Liabilities	-7.9%	1,319	1,432	1,997	2,178	4,012	1,733	1,693	1,826	1,159	1,970	1,805	983	1,074	1,157	983	1,148	410	459	529	1,569	495
Shareholder's Equity	5.8%	8,146	7,702	7,241	8,482	7,918	21,259	22,033	18,328	22,298	36,643	39,293	43,491	8,515	10,688	12,696	13,740	12,032	8,049	4,688	1,888	3,186
Retained Earnings	0.5%	-93,566	-93,990	-94,363	-93,191	-93,724	-81,270	-80,447	-84,103	-78,802	-64,281	-61,266	-56,726	-54,083	-50,709	-48,565	-47,858	-45,511	-41,455	-39,070	-36,018	-34,633
Additional Paid-In Capital	0.0%	101,711	101,691	101,603	101,671	101,641	102,468	102,419	102,369	101,099	100,900	100,536	100,193	62,583	61,309	61,173	61,513	57,531	49,454	43,736	37,886	37,799
Shares Outstanding	0%	1,275	1,275	1,267	1,267	1,267	1,084	1,009	783	489	489	489	427	303	-	-	-	-	-	-	-	-
Float	-	-	-	9,900	-	-	-	9,200	-	-	-	41,800	-	-	-	37,500	-	-	-	20,800	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-71.9%	-1,317	-766	-406	-1,879	-1,363	-1,282	-2,574	-2,226	-1,566	-1,792	-4,865	-2,420	-2,173	-1,819	-2,285	-1,735	-1,840	-1,695	-1,907	-586	-885
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-251	1,402	68.00	78.00	57.00	187	56.00	190
Cashflow From Investing	-	20.00	-	-2.14	-1.65	-	10,004	1,990	-7,003	2,096	-145	-	-	-	6.00	-	-40.73	-7.97	-104	-54.12	-4.82	-31.93
Cashflow From Financing	-100.0%	-	58.00	-	-5,250	4,323	-	-24.01	9,969	-1*	-	1*	37,231	897	6.00	999	3,551	7,409	4,986	4,156	94.00	487

GHSI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 12,248,550	$ 11,049,772
Cost of goods sold
Total cost of goods sold	6,854,033	6,529,385
Gross profit	5,394,517	4,520,387
Operating expenses
Research and development	150,684	193,800
Sales and marketing	1,704,680	2,069,660
General and administrative	7,480,925	9,577,987
Transaction costs related to pending disposition of business	394,546
Impairment of intangible assets		10,065,833
Impairment of right-of-use asset		24,257
Loss on disposal of fixed assets		9,448
Total operating expenses	9,730,834	21,940,985
Loss from operations	(4,336,317)	(17,420,598)
Other income (expense):
Change in fair value of warrant derivative liability	3,984,900	2,345,800
Gain on disposal of VectorVision subsidiary	129,930
Interest income, net	379,520	152,570
Total other income (expense)	4,494,350	2,498,370
Net income (loss)	158,033	(14,922,228)
Preferred stock deemed dividend		941,585
Net income (loss) available to common stockholders	$ 158,033	$ (15,863,813)
Net income (loss) per common share - basic	$ 0.12	$ (14.15)
Net income (loss) per common share - diluted	$ 0.12	$ (14.15)
Weighted average common shares outstanding - basic	1,270,846	1,121,000
Weighted average common shares outstanding - diluted	1,270,846	1,121,000
Nutritional supplements [Member]
Revenue
Total revenue	$ 11,907,867	$ 10,640,119
Cost of goods sold
Total cost of goods sold	6,594,082	6,171,641
Ocular Products and Other [Member]
Revenue
Total revenue	340,683	409,653
Ocular Products [Member]
Revenue
Total revenue	340,683	390,934
Cost of goods sold
Total cost of goods sold	$ 259,951	$ 357,744

GHSI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 6,359,646	$ 10,655,490
Restricted cash		5,250,000
Accounts receivable, net	2,274,394	1,924,353
Inventories	2,677,112	3,119,421
Prepaid expenses and other current assets	573,780	687,933
Total current assets	11,884,932	21,637,197
Property and equipment, net	33,245	48,871
Total assets	11,918,177	21,686,068
Current liabilities
Accounts payable	614,122	1,518,052
Accrued expenses	704,912	558,287
Operating lease liability - current		3,807
Warrant derivative liability – current		1,931,400
Total current liabilities	1,319,034	4,011,546
Warrant derivative liability – long-term	2,453,100	4,506,600
Total liabilities	3,772,134	8,518,146
Commitments and contingencies
Redeemable preferred stock
Total redeemable preferred stock		5,250,000
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized
Common stock, $0.001 par value; 250,000,000 shares authorized; 1,275,239 shares and 1,267,340 shares issued and outstanding on December 31, 2023 and 2022, respectively	1,275	1,267
Additional paid-in capital	101,711,035	101,640,955
Accumulated deficit	(93,566,267)	(93,724,300)
Total stockholders’ equity	8,146,043	7,917,922
Total liabilities, redeemable preferred stock, and stockholders’ equity	11,918,177	21,686,068
Series C Convertible Redeemable Preferred Stock [Member]
Redeemable preferred stock
Total redeemable preferred stock		5,197,500
Series D Redeemable Preferred Stock [Member]
Redeemable preferred stock
Total redeemable preferred stock		$ 52,500

About Guardion Health Sciences Inc

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

CEO	Ms. Janet Hall
WEBSITE	guardionhealth.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	12

Guardion Health Sciences Inc Frequently Asked Questions

What is the ticker symbol for Guardion Health Sciences Inc? What does GHSI stand for in stocks?

GHSI is the stock ticker symbol of Guardion Health Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Guardion Health Sciences Inc (GHSI)?

As of Fri Apr 19 2024, market cap of Guardion Health Sciences Inc is 10.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GHSI stock?

You can check GHSI's fair value in chart for subscribers.

What is the fair value of GHSI stock?

You can check GHSI's fair value in chart for subscribers. The fair value of Guardion Health Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Guardion Health Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GHSI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Guardion Health Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether GHSI is over valued or under valued. Whether Guardion Health Sciences Inc is cheap or expensive depends on the assumptions which impact Guardion Health Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GHSI.

What is Guardion Health Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, GHSI's PE ratio (Price to Earnings) is 64.93 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GHSI PE ratio will change depending on the future growth rate expectations of investors.